Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Form 8 (OPD)

17 Dec 2019 16:36

RNS Number : 2213X
Open Orphan PLC
17 December 2019
 

The Form 8 announcement released on 17/12/19 at 10:19 under RNS No 0632X has been amended.

 

The full amended text is shown below.

 

Open Orphan plc

 

("Open Orphan" or the "Company")

 

Disclosure under rule 8.1 and 8.2 of the Takeover Code

 

In accordance with Takeover code rule 8.1, the Company makes the following announcement:

 

 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Open Orphan plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Open Orphan plc

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

13 December 2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary Shares of 0.1p each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

None

None

(2) Cash-settled derivatives:

 

None

None

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

None

None

 

TOTAL:

None

None

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Details of Concert Party shareholdings:

 

Current

% of current total

Raglan Road Capital Limited

21,536,124

8.46%

Pamela Iver

14,880,721

5.85%

Horizon Medical Technologies Limited

4,630,136

1.82%

Anthony Richardson

16,313,388

6.41%

Brendan Buckley

7,845,860

3.08%

Crow Rock Capital Limited

7,845,860

3.08%

Dairine Dempsey

3,138,344

1.23%

Ian O'Connell

3,138,344

1.23%

Montana Capital Limited

1,376,466

0.54%

Clydagh Limited

1,376,466

0.54%

Pat O'Neill

1,569,172

0.62%

McNolan Ventures Limited

470,974

0.19%

Carol Dalton

313,983

0.12%

Bridget Chisolm

313,983

0.12%

Ross Crocket

313,983

0.12%

Dennis Jennings

1,003,332

0.39%

Tom Tierney

2,006,665

0.79%

Mount Amber International Limited

5,016,291

1.97%

Francoise Richardson

1,805,136

0.71%

Gary Duffy

539,654

0.21%

 

 

 

Details of concert party options/warrants:

 

Options over Open Orphan shares

Raglan Road Capital Limited

3,250,000

Cathal Friel CMF Pension Fund

657,285

Dan Cronin

539,654

Michael Fleming

269,866

Pa Nolan

269,866

Maurice Treacy*

7,716,964

 

Details of Director shareholdings (excluding those in the Concert Party)

 

Options over Open Orphan shares

Michael Ryan

134,586

 

 

Details of Director options (excluding those in the Concert Party)

 

Options over Open Orphan shares

Grant date

Exercise price per share (pence)

Expiry date

Christian Milla

770,000

14/09/2017

13

13/09/2027

Michael Ryan

200,000

14/09/2017

13

13/09/2027

 

*Maurice Treacy's options were granted on 28/06/2019, with an exercise price per share of 5.6 pence and expiry date of 27/06/2022

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

17 December 2019

Contact name:

Cathal Friel, Chief Executive Officer

Telephone number:

+353 (0)1 644 0007

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFMMMZVNFGLZM
Date   Source Headline
28th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSAppointment of Non Executive Director
13th Sep 20167:00 amRNSDirectorate Change
24th Aug 20167:00 amRNSNotice of Results
3rd Aug 20167:00 amRNSContract wins
30th Jun 201612:18 pmRNSResult of AGM
30th Jun 20167:00 amRNSAGM Statement
20th Jun 20164:24 pmRNSShareholder notification
10th Jun 201611:05 amRNSPosting of Annual Report and Notice of AGM
10th May 20167:00 amRNSFinal Results
24th Mar 20167:00 amRNSYear End Update
18th Jan 20168:00 amRNSEnterprise Securities Market Notice
13th Jan 20167:00 amRNSESM Schedule 1 update
13th Jan 20167:00 amRNSESM Appendix to Schedule 1 update
12th Jan 20167:00 amRNSContracts worth EUR 3.4m signed with US Biotech
8th Jan 20162:03 pmRNSHolding(s) in Company
8th Jan 20167:01 amRNSTrading update
8th Jan 20167:00 amRNSDirectorate Change
11th Dec 20157:00 amRNSChange of Adviser
11th Dec 20157:00 amRNSESM Pre-Admission Announcement
11th Dec 20157:00 amRNSAppendix to Schedule 1 announcement
3rd Nov 20157:00 amRNSGrant of Share Option & Total Voting Rights
23rd Oct 20157:00 amRNSContract for over EUR1m with French Biotech
19th Oct 20157:00 amRNSAppointment of Director
19th Oct 20157:00 amRNSCompletion of the Acquisition of Kinesis Pharma BV
9th Oct 201511:38 amRNSResult of General Meeting & Update on Acquisition
22nd Sep 20157:01 amRNSHalf Yearly Report
22nd Sep 20157:00 amRNSProposed acquisition & Placing
24th Aug 20152:00 pmRNSAppointment of Co-Broker
21st Aug 20157:00 amRNSNotice of Results
13th Aug 20157:00 amRNSTrading update
30th Jun 201511:39 amRNSResult of AGM
30th Jun 20157:00 amRNSAGM Statement
15th Jun 20157:00 amRNSAppointment of Chief Financial Officer
10th Jun 20153:46 pmRNSEUR 2m contract with leading European biotech
28th May 201510:14 amRNSPosting of Annual Report & Notice of AGM
22nd May 20157:00 amRNSFinal Results
20th May 20153:29 pmRNSHolding(s) in Company
20th May 20157:00 amRNSNew services from Innovenn
12th May 20157:01 amRNSDirectorate Change
8th Apr 20159:06 amRNSHolding(s) in Company
8th Apr 20159:05 amRNSHolding(s) in Company
7th Apr 20152:39 pmRNSHolding(s) in Company
7th Apr 201511:17 amRNSHolding(s) in Company
2nd Apr 20152:00 pmRNSInvestor teach-in
2nd Apr 20157:00 amRNSInnoVenn expands products and first sales in US
1st Apr 201512:14 pmRNSResult of General Meeting
30th Mar 20157:00 amRNSContracts for EUR4.1m with US Biotech client
13th Mar 20154:45 pmRNSPlacing to raise £2 million
6th Mar 20157:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.